Affini-T Therapeutics

Recent Finacing

Equity

Recent Raise

$175M

Affini-T engineers T cells combining high-activity TCRs and synthetic biology switches to improve function and tumor infiltration, targeting mutant KRAS and advancing programs from Seattle research to Boston manufacturing.

Founded 2021

Massachusetts, United States

101-250

Private

affinittx.com

Highlights

Focus Areas

Biotechnology

Health Care

Therapeutics

Recent Investors

E

Financials

$175M

Total Raised

1

Funding round

9

Investors

Team

Upgrade to view the team

See the team members at Affini-T Therapeutics.